Eliem Therapeutics (NASDAQ:ELYM) Stock Price Down 4.3% - Should You Sell?

Key Points

• Eliem Therapeutics' stock fell by 4.3%, trading between $2.01 and $2.02, with a notable increase in trading volume at approximately 837,446 shares.
• The company's market cap is $60.10 million and it has a negative PE ratio of -3.81, indicating losses relative to its market price.
• Eliem Therapeutics is focused on developing therapies for neuronal excitability disorders across various conditions including psychiatry and chronic pain.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report)'s stock price fell 4.3% during mid-day trading on Wednesday . The company traded as low as $2.01 and last traded at $2.02. 837,446 shares were traded during trading, an increase of 72% from the average session volume of 486,688 shares. The stock had previously closed at $2.11.

Eliem Therapeutics Price Performance

The business has a fifty day moving average of $1.53 and a 200-day moving average of $1.39. The stock has a market capitalization of $73.78 million, a price-to-earnings ratio of -4.68 and a beta of -0.39.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.